Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Levetiracetam
Drug ID BADD_D01265
Description Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.[A185927]
Indications and Usage Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.[L8606] Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.[L8609]
Marketing Status approved
ATC Code N03AX14
DrugBank ID DB01202
KEGG ID D00709
MeSH ID D000077287
PubChem ID 5284583
TTD Drug ID D0E1XL
NDC Product Code 76494-528; 36998-5960; 0904-7265; 58032-0132; 66174-0044; 16729-064; 25021-780; 27808-263; 31722-537; 42385-956; 42385-957; 43063-499; 43063-617; 43485-102; 44567-501; 47335-573; 47335-576; 50090-1333; 50090-2456; 50405-302; 51224-013; 51672-4137; 51672-4143; 55150-177; 60687-668; 61919-559; 62135-548; 63739-019; 63739-787; 66689-030; 67296-1486; 67877-770; 67877-771; 68180-112; 68180-118; 69102-105; 70518-3317; 71930-064; 72205-037; 76282-248; 80705-101; 55111-870; 65862-245; 72643-025; 82623-501; 13668-015; 13668-017; 14789-110; 16571-789; 16571-790; 27808-264; 0121-4799; 43485-103; 43547-223; 43547-345; 44567-503; 51672-4142; 60687-657; 63187-360; 63739-158; 63739-411; 64980-362; 67296-1248; 68001-405; 0409-2011; 68382-168; 69102-106; 70518-1772; 70518-3742; 70518-3765; 71205-880; 0615-7979; 72205-095; 12666-0014; 28877-5950; 36998-0117; 51927-0088; 57572-0034; 64220-192; 65372-1148; 72640-004; 16714-537; 16729-067; 27808-266; 42385-954; 0143-9574; 43485-104; 50474-597; 51672-4136; 61919-552; 63629-4137; 63629-8315; 64980-364; 64980-365; 65862-247; 65862-250; 66689-029; 68001-113; 68083-152; 68084-882; 68084-893; 69367-332; 70860-602; 71093-144; 71335-0748; 71335-2098; 0615-7978; 71930-063; 72189-190; 64980-363; 65162-685; 65841-703; 65841-704; 66689-028; 67457-265; 67457-266; 68083-154; 68180-114; 68382-165; 68788-7430; 70518-1998; 72189-229; 76494-529; 82009-123; 0904-7124; 62512-0030; 65862-246; 65862-261; 65862-315; 75834-246; 13668-014; 16714-310; 16714-357; 16729-065; 24689-106; 0143-9673; 47133-574; 50228-473; 60429-349; 63629-4675; 0378-5615; 65162-538; 66689-102; 67877-769; 68084-859; 68180-113; 0409-1886; 0472-0235; 70518-1827; 71205-728; 71205-881; 71335-0139; 71335-0702; 72205-096; 72485-106; 76494-531; 82009-122; 36998-5950; 38779-2900; 51927-0155; 64220-152; 71901-605; 81414-001; 16729-066; 31722-539; 42385-955; 43547-454; 50228-470; 50405-303; 55111-181; 63739-795; 67877-768; 68001-403; 68071-4508; 68083-153; 68084-870; 68180-099; 68788-7884; 70518-1921; 71930-065; 72205-120; 72865-188; 76282-246; 76494-530; 36998-5980; 36998-5990; 42185-7039; 51552-1448; 52038-171; 69037-0074; 71052-043; 16714-034; 16714-035; 16714-355; 16714-356; 35208-031; 35208-032; 0121-1598; 42571-331; 43547-221; 43547-222; 50090-6378; 50228-190; 50228-471; 50268-470; 50474-002; 50474-598; 50474-599; 55111-182; 55111-183; 55154-4171; 55154-5782; 60505-3517; 60505-3518; 63323-400; 0378-5619; 65162-528; 65162-529; 68001-404; 68788-8254; 69102-107; 70518-1108; 70518-2109; 70518-3534; 70860-604; 71335-0694; 72572-360; 72865-189; 82009-124; 28877-5960; 68225-021; 13668-016; 14789-330; 16571-787; 16714-358; 0121-0799; 43547-224; 43547-346; 44567-502; 50090-3889; 50228-189; 60429-350; 60505-3280; 60687-249; 63629-9615; 65162-539; 68180-117; 70518-3769; 70860-603; 71930-062; 72205-097; 72789-152; 80705-100; 82009-121; 0904-7125; 62991-3189; 16571-788; 31722-574; 44567-500; 47133-575; 50090-2875; 50090-6086; 50383-241; 50405-301; 51079-821; 51672-4141; 55154-5699; 63629-7516; 0378-5617; 67457-255; 68001-114; 68001-402; 68180-115; 69102-108; 69339-157; 69367-333; 70518-0947; 70518-1796; 70518-1901; 70518-2230; 75834-245; 76282-247; 28877-0117; 28877-5970; 50683-0322; 62350-0059; 68554-0065; 14789-220; 16714-354; 31722-536; 39822-4000; 50228-472; 50405-300; 51655-325; 58118-1112; 61919-685; 67457-790; 70518-3770; 71335-0048; 0615-7976; 0615-7977; 72205-094; 72865-187; 72865-190; 0904-7123; 36998-5940; 36998-5970; 62331-010; 67835-0006; 27808-265; 31722-538; 0121-2397; 43485-101; 50474-001; 50474-594; 50474-595; 50474-596; 51991-651; 55111-248; 55154-3367
UNII 44YRR34555
Synonyms Levetiracetam | Etiracetam, S-isomer | Etiracetam, S isomer | S-isomer Etiracetam | Ucb L059 | Ucb-L059 | UCB 6474 | UCB-6474 | UCB6474 | Etiracetam, R-isomer | Etiracetam, R isomer | R-isomer Etiracetam | Etiracetam, (R)- | Keppra | Etiracetam | alpha-ethyl-2-oxo-1-Pyrrolidineacetamide | alpha ethyl 2 oxo 1 Pyrrolidineacetamide | Ucb L060 | Ucb-L060 | UcbL060
Chemical Information
Molecular Formula C8H14N2O2
CAS Registry Number 102767-28-2
SMILES CCC(C(=O)N)N1CCCC1=O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cachexia14.03.02.001; 08.01.01.009; 16.32.03.0110.000318%Not Available
Capillary fragility24.03.02.001; 23.06.04.0020.000199%Not Available
Cardiac arrest02.03.04.001--
Cardiomegaly02.04.02.0010.000254%Not Available
Catatonia19.11.01.0010.000318%Not Available
Cerebellar ataxia17.02.02.013; 08.01.02.0060.000278%Not Available
Cerebellar syndrome17.02.02.0020.000079%Not Available
Cerebral atrophy17.11.01.0010.000119%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.001312%Not Available
Cerebrospinal fluid leakage12.01.10.004; 17.02.05.0010.000119%
Cerebrovascular disorder24.03.05.002; 17.08.02.0020.000079%Not Available
Chest pain22.12.02.003; 02.02.02.011; 08.01.08.002--Not Available
Chills08.01.09.001; 15.05.03.016--
Choking22.12.03.0030.000199%Not Available
Cholestasis09.01.01.0010.002027%Not Available
Chorea17.01.01.0010.000079%Not Available
Choreoathetosis17.01.01.0030.000390%Not Available
Circulatory collapse24.06.02.0010.000715%Not Available
Clonus17.02.05.0020.000278%Not Available
Clumsiness17.01.02.0050.000437%Not Available
Coagulopathy01.01.02.0010.000795%Not Available
Cold sweat23.02.03.002; 08.01.03.024--Not Available
Colitis ulcerative10.02.01.004; 07.08.01.005--Not Available
Coma17.02.09.0010.001630%Not Available
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Condition aggravated08.01.03.0040.007560%Not Available
Confusional state19.13.01.001; 17.02.03.0050.004929%
Conjunctivitis11.01.06.012; 06.04.01.002--
Conjunctivitis allergic10.01.04.002; 06.04.01.0030.000119%Not Available
Constipation07.02.02.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 25 Pages